Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Global Outlook and Forecast 2022-2028

March 2022 | 60 pages | ID: A67B19420A2EEN
Market Monitor Global

Abstracts

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.

This report contains market size and forecasts of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Global, including the following market information:

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Glassia Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Alpha-1 Antitrypsin Deficiency Augmentation Therapy include Grifols, CSL, Baxter, Kamada, Takeda and Abeona, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Alpha-1 Antitrypsin Deficiency Augmentation Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Type, 2021 (%)

• Glassia
• Aralast NP
• Prolastin C
• Others

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Specialty Clinics

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Grifols
• CSL
• Baxter
• Kamada
• Takeda
• Abeona

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY OVERALL MARKET SIZE

2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size: 2021 VS 2028
2.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market
3.2 Top Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies Ranked by Revenue
3.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Companies
3.4 Top 3 and Top 5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Markets, 2021 & 2028
  4.1.2 Glassia
  4.1.3 Aralast NP
  4.1.4 Prolastin C
  4.1.5 Others
4.2 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
  4.2.1 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2022
  4.2.2 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2023-2028
  4.2.3 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Specialty Clinics
5.2 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
  5.2.1 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2022
  5.2.2 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2023-2028
  5.2.3 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2021 & 2028
6.2 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
  6.2.1 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2022
  6.2.2 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2023-2028
  6.2.3 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028
  6.3.2 US Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.3.3 Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.3.4 Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028
  6.4.2 Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.3 France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.4 U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.5 Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.6 Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.4.8 Benelux Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028
  6.5.2 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.5.3 Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.5.4 South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.5.6 India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028
  6.6.2 Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.6.3 Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028
  6.7.2 Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.7.3 Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028
  6.7.5 UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Grifols
  7.1.1 Grifols Corporate Summary
  7.1.2 Grifols Business Overview
  7.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.1.4 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.1.5 Grifols Key News
7.2 CSL
  7.2.1 CSL Corporate Summary
  7.2.2 CSL Business Overview
  7.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.2.4 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.2.5 CSL Key News
7.3 Baxter
  7.3.1 Baxter Corporate Summary
  7.3.2 Baxter Business Overview
  7.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.3.4 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.3.5 Baxter Key News
7.4 Kamada
  7.4.1 Kamada Corporate Summary
  7.4.2 Kamada Business Overview
  7.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.4.4 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.4.5 Kamada Key News
7.5 Takeda
  7.5.1 Takeda Corporate Summary
  7.5.2 Takeda Business Overview
  7.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.5.4 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.5.5 Takeda Key News
7.6 Abeona
  7.6.1 Abeona Corporate Summary
  7.6.2 Abeona Business Overview
  7.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
  7.6.4 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2017-2022)
  7.6.5 Abeona Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Opportunities & Trends in Global Market
Table 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers in Global Market
Table 3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints in Global Market
Table 4. Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Global Market
Table 5. Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type
Table 9. List of Global Tier 1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Grifols Corporate Summary
Table 31. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 32. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)
Table 33. CSL Corporate Summary
Table 34. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 35. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Baxter Corporate Summary
Table 37. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 38. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)
Table 39. Kamada Corporate Summary
Table 40. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 41. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Takeda Corporate Summary
Table 43. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 44. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Abeona Corporate Summary
Table 46. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 47. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Type in 2021
Figure 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Application in 2021
Figure 3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2021
Figure 8. By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 12. US Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 24. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)